Post-traumatic Stress Disorder Clinical Trial
Official title:
The Effectiveness of a Cognitive Training Program, Goal Management Training, on Reducing Cognitive Difficulties and Improving Every-day Functioning in Individuals With Affective Disorders
This study investigates the utility of Goal Management Training (GMT) in patients with post-traumatic stress disorder (PTSD), in order to determine if this treatment is effective in improving cognitive function in patients with frontal-temporally mediated brain dysfunction. Specifically, the primary aim of this study is to examine whether a standardized 9-week program of GMT results in durable improvements in cognitive functioning relative to a wait-list control group. A secondary aim will be to determine whether participation in the GMT group is associated with long-term functional improvements. It is hypothesized that at post-treatment, participants with PTSD assigned to the GMT groups will show greater improvement in neuropsychological test performance and greater functional improvement compared to those in the wait-list group; these gains are expected to be maintained at 3 month follow-up.
Given the potentially devastating impact of poor cognitive functioning on the ability of
patients with PTSD to benefit from treatment interventions, and its association with poor
functional outcomes, there is an urgent need to identify novel treatment interventions aimed
at reducing cognitive dysfunction in these disorders. Accordingly, the aim of the present
proposal is to conduct a randomized controlled trial among patients with PTSD, examining the
efficacy of a well-established cognitive intervention (in the treatment of cognitive
deficits), aimed at reducing attentional and executive dysfunction, known as Goal Management
Training® (GMT) (See Levine et al., 2011). A secondary aim is to determine the longer-term
impact of the GMT approach on functional outcomes.
The participants include 48 men and women with a primary diagnosis of with stable symptoms at
the time of baseline assessment and reporting alterations in memory, attention, or executive
functioning. Participants will be recruited from multiple sites: an inpatient post-traumatic
stress recovery program in Ontario, Canada, and the program's external referral agencies that
also service clients via outpatient services/ programs, external community agencies and
support groups, and through social media.
Following determination of eligibility, participants will be randomly assigned, by using the
randomized table of numbers method, to either: 1) a 9-week GMT program or 2) a 9-week
wait-list control (WLC) condition (see Figure 1). Participants will be invited to attend a
baseline testing session 1 prior to group commencement (approximately 4 hours in duration)
where written consent will be obtained prior to any collection of data. Once the testing
session is complete, the participants will be given information about what group they have
been assigned to (GMT or WLC).
Participants enrolled in the GMT program attended the 9-week GMT sessions (2 hours/week for 9
weeks) and a post-intervention testing session date (1-2 weeks following the completion of
the GMT; approximately 3 hours in duration). Participants enrolled in the WLC control group
attended a testing session date after 9 weeks has past (approximately 3 hours in duration).
As each participant completed a post-intervention testing session (both GMT and WLC), they
will be setup with the final testing session (in 3 months' time; approximately 3 hours in
duration). WLC were offered a complimentary 9-week GMT program once the final testing session
is complete. Following the completion of the complimentary 9-week GMT program, individuals in
the WLC completed a post-intervention testing (1-2 weeks following the completion of GMT and
again at 3 months, post GMT completion).
These data will be analyzed using 2 x 3 mixed-design split plot factorial ANCOVAs that treat
Group (GMT vs. WLC) as a between-subjects factor and Time (baseline, post-intervention, 3
months; subjects nested within groups) as a within-subjects factor. In addition,
within-subjects analyses of covariance (ANCOVAS) treating time (baseline, post-intervention,
3 months) as a within-subjects factor will be carried out on data collected from the GMT
group and from the WLC group after they have completed the GMT arm of the study. PTSD symptom
severity (CAPS), depressive symptom severity (BDI-II), severity of past trauma exposure
(CTQ), and medication load, and additional psychological treatment (treatment information
form) will serve as covariates in this model. Tukey's Honestly Significant Difference
post-hoc test will be used for follow-up pair-wise comparisons of between-subjects'
variables.
It is hypothesized that, post-treatment, participants with PTSD assigned to the GMT group
will show significantly greater improvement in neuropsychological test performance and
greater functional improvement compared to participants in the wait-list control group; these
gains are expected to be maintained at 3-month-follow-up.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04317820 -
Deep Brain Reorienting in Post-traumatic Stress Disorder
|
N/A | |
Completed |
NCT05112003 -
Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot
|
N/A | |
Recruiting |
NCT04518267 -
Anger and Psychotrauma: Data From Military and Civilians
|
||
Completed |
NCT02502604 -
Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Terminated |
NCT02234687 -
A mGlu2/3 Agonist in the Treatment of PTSD
|
Phase 1 | |
Completed |
NCT02213900 -
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
|
Phase 4 | |
Terminated |
NCT02520726 -
PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims
|
Phase 4 | |
Completed |
NCT01738308 -
The Effects of Healing Touch on Post Operative Pediatric Patients
|
N/A | |
Completed |
NCT01437891 -
Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF)
|
N/A | |
Completed |
NCT01517711 -
Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)
|
Phase 4 | |
Completed |
NCT01998100 -
Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD)
|
Phase 3 | |
Completed |
NCT01199107 -
Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)
|
Phase 3 | |
Completed |
NCT01231711 -
Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention
|
Phase 1 | |
Completed |
NCT00838006 -
Psychophysiologic Predictors of Post-deployment Mental Health Outcomes
|
N/A | |
Completed |
NCT00680524 -
Telephone-based Care for OEF/OIF Veterans With PTSD
|
N/A | |
Completed |
NCT00348036 -
Group Intervention for Interpersonal Trauma
|
N/A | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00183690 -
Prolonged Exposure Therapy Versus Active Psychotherapy in Treating Post-Traumatic Stress Disorder in Adolescents
|
Phase 1 | |
Completed |
NCT00127673 -
Comparison of Two Treatments for Post-Traumatic Stress Disorder
|
Phase 3 |